search
Back to results

Combined Antihypertensive Therapy and Sexual Dysfunction

Primary Purpose

Hypertension, Sexual Dysfunction

Status
Unknown status
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Felodipine add Irbesartan
Felodipine add Metoprolol
Sponsored by
LanZhou University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension focused on measuring Hypertension, Antihypertensive Agents, Combination, Sexual Dysfunction, Oxidative Stress

Eligibility Criteria

18 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with essential hypertension.
  • Initial hypertension, or without taking any antihypertensive for at least one month.
  • Sexual active.

Exclusion Criteria:

  • Patients with secondary hypertension.
  • Patients with malignant hypertension, coronary heart disease, diabetes, a history of syncope, bradycardia (heart rate <45 beats / min), atrioventricular block(Ⅱ or Ⅲ degree), sick sinus syndrome, congestive heart failure, a history of cerebral vascular accidents, serious hepatic and kidney dysfunction, a history of serious mental illness, pregnant, taking oral exogenous estrogens (including contraceptives), hysterectomy, breastfeeding, a history of alcohol or drug abuse, having serious conflict with sexual partner, severity sexual dysfunction.
  • Patients refuse to answer questions, refuse to fill in the questionaires,or do not willing to take blood examination.

Sites / Locations

  • The Second Hospital of Lanzhou UniversityRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Felodipine,Irbesartan,Sexual Dysfunction

Felodipine,Metoprolol,Sexual Dysfunction

Arm Description

Outcomes

Primary Outcome Measures

Female Sexual Function Index (FSFI)
The Female Sexual Function Index (FSFI) is a multidimensional self-report scale for assessing sexual function in women.The FSFI hase been validated in women with various sexual disorders,and in non-dysfunctional controls showing good discriminant validity,internal consistency,and test-retest reliability.
International Index of Erectile Function(IIEF)
The 15-item International Index of Erectile Function (IIEF) was developed to diagnose the presence and severity of erectile dysfunction (ED).

Secondary Outcome Measures

Change of Systolic Blood Pressure in 2 Weeks
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week. BP is measured using a calibrated standard mercury sphygmomanometer.After the patient has been seated for 15 minutes,sitting BP is measured 2 times at 1- to 2-minutes intervals,The mean of 2 sitting BP measurements is used as the sitting BP value for that visit;If the difference between the 2 measurements is over 5mmHg,BP should be measured again, and the average of 3 measurements will be taken.
Change of Systolic Blood Pressure in 4 Weeks
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Change of Systolic Blood Pressure in 8 Weeks
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Change of Systolic Blood Pressure in 12 Weeks
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week
Change of Systolic Blood Pressure in 24 Weeks
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Change of Systolic Blood Pressure in 48 Weeks
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week
Change of Diastolic Blood Pressure in 2 Weeks
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week
Change of Diastolic Blood Pressure in 4 Weeks
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week
Change of Diastolic Blood Pressure in 8 Weeks
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week
Change of Diastolic Blood Pressure in 12 Weeks
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Change of Diastolic Blood Pressure in 24 Weeks
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Change of Diastolic Blood Pressure in 48 Weeks
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Serum Estradiol in 24 Weeks
Fasting blood samples are taken at 8:00-10:00.After quiescence for 1h and centrifuged (3500rpm/min * 15min), serum samples are extracted and preserved in -80 ℃. Use hemiluminescent radioimmunoassay to detect the level of estradiol in serum sample.
Serum Estradiol in 48 Weeks
Serum Testosterone in 24 Weeks
Fasting blood samples are taken at 8:00-10:00.After quiescence for 1h and centrifuged (3500rpm/min * 15min), serum samples are extracted and preserved in -80 ℃. Use hemiluminescent radioimmunoassay to detect the level of testosterone in serum sample.
Serum Testosterone in 48 Weeks
Serum MDA in 24 Weeks
Among many oxidative stress biological indicators,malondialdehyde (MDA),the secondary products of lipid peroxidation,is the most representative and most studied polyunsaturated fatty acid peroxidation. Fasting blood samples are taken at 8:00-10:00.After quiescence for 1h and centrifuged (3500rpm/min * 15min), serum samples are extracted and preserved in -80 ℃. Use ELISA to detect the level of MDA in serum samples.
Serum MDA in 48 Weeks
Serum 8-OHdG in 24 Weeks
Reactive oxygen species (ROS) produced either endogenously or exogenously can attack lipid, protein and nucleic acid simultaneously in the living cells. In nuclear and mitochondrial DNA, 8-hydroxydeoxyguanosine (8-OHdG) is produced during DNA repair and its measurement be useful as a marker of DNA lesion. Fasting blood samples are taken at 8:00-10:00.After quiescence for 1h and centrifuged (3500rpm/min * 15min), serum samples are extracted and preserved in -80 ℃. Use ELISA to detect the level of 8-OHdG in serum samples.
Serum 8-OHdG in 48 Weeks
Serum HNE in 24 Weeks
4 - hydroxy-nonyl acid (HNE) is a strong toxicity end product of lipid peroxidation. Fasting blood samples are taken at 8:00-10:00.After quiescence for 1h and centrifuged (3500rpm/min * 15min), serum samples are extracted and preserved in -80 ℃. Use ELISA to detect the level of HNE in serum samples.
Serum HNE in 48 Weeks

Full Information

First Posted
October 12, 2010
Last Updated
November 10, 2010
Sponsor
LanZhou University
search

1. Study Identification

Unique Protocol Identification Number
NCT01238705
Brief Title
Combined Antihypertensive Therapy and Sexual Dysfunction
Official Title
Effect of Combined Antihypertensive Therapy on Blood Pressure and Sexual Function in Patients With Essential Hypertension
Study Type
Interventional

2. Study Status

Record Verification Date
November 2010
Overall Recruitment Status
Unknown status
Study Start Date
April 2008 (undefined)
Primary Completion Date
October 2010 (Anticipated)
Study Completion Date
November 2010 (Anticipated)

3. Sponsor/Collaborators

Name of the Sponsor
LanZhou University

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This randomized,active controlled study aimed to compare the effects on sexual function of treatment with combined antihypertensive drugs. The researchers hypothesize that: Both felodipine-irbesartan combination and felodipine-metoprolol combination are effective in lowing blood pressure in patients with essential hypertension. Felodipine-metoprolol combination induces a worse sexual function and a reduction of sex hormone,whereas felodipine-irbesartan combination does not impair sexual function and does not change hormone levels. Oxidative stress decline after both combination regimens. Felodipine-irbesartan combination has a greater impact on oxidative stress indicators than felodipine-metoprolol combination.
Detailed Description
The effects of hypertension and its pharmacotherapy on sexual function are well known in men,although this topic remains unexplored in women.There is evidence suggests that some classes of antihypertensive drugs such as diuretics and beta-blockers have more negative impact on male sexual function than other classes such as calcium channel blockers(CCBs) and angiotensin-converting enzyme inhibitors(ACEI).Some data suggest that angiotensin Ⅱ antagonists(ARBs) not only do not exacerbate sexual function in males,but even improve it. Treatment with multiple antihypertensive medications was often necessary to attain blood-pressure goals recommended by guidelines.More than two third of patients with 2 or 3 degree of essential hypertension require combination therapy at the beginning of treatment to avoid target organ damage and to minimize the accidence of adverse events. CCBs were recommended by both JNC-7 and ESH / ESC 2007 hypertension guidelines as the basic for the treatment of hypertension.The purpose of this study is to compare the impacts of different CCB-based antihypertensive drugs combination on sexual behavior in both male and female patients with essential hypertension,thus provide evidences for physicians to increase patients adherence to the treatment regimens beside lowing blood pressure.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension, Sexual Dysfunction
Keywords
Hypertension, Antihypertensive Agents, Combination, Sexual Dysfunction, Oxidative Stress

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
280 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Felodipine,Irbesartan,Sexual Dysfunction
Arm Type
Active Comparator
Arm Title
Felodipine,Metoprolol,Sexual Dysfunction
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Felodipine add Irbesartan
Other Intervention Name(s)
Plendil, Aprovel
Intervention Description
Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415. Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074.
Intervention Type
Drug
Intervention Name(s)
Felodipine add Metoprolol
Other Intervention Name(s)
Plendil, Betaloc
Intervention Description
Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415. Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061.
Primary Outcome Measure Information:
Title
Female Sexual Function Index (FSFI)
Description
The Female Sexual Function Index (FSFI) is a multidimensional self-report scale for assessing sexual function in women.The FSFI hase been validated in women with various sexual disorders,and in non-dysfunctional controls showing good discriminant validity,internal consistency,and test-retest reliability.
Time Frame
48 weeks
Title
International Index of Erectile Function(IIEF)
Description
The 15-item International Index of Erectile Function (IIEF) was developed to diagnose the presence and severity of erectile dysfunction (ED).
Time Frame
48 weeks
Secondary Outcome Measure Information:
Title
Change of Systolic Blood Pressure in 2 Weeks
Description
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week. BP is measured using a calibrated standard mercury sphygmomanometer.After the patient has been seated for 15 minutes,sitting BP is measured 2 times at 1- to 2-minutes intervals,The mean of 2 sitting BP measurements is used as the sitting BP value for that visit;If the difference between the 2 measurements is over 5mmHg,BP should be measured again, and the average of 3 measurements will be taken.
Time Frame
2 weeks
Title
Change of Systolic Blood Pressure in 4 Weeks
Description
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Time Frame
4 weeks
Title
Change of Systolic Blood Pressure in 8 Weeks
Description
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Time Frame
8 weeks
Title
Change of Systolic Blood Pressure in 12 Weeks
Description
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week
Time Frame
12 weeks
Title
Change of Systolic Blood Pressure in 24 Weeks
Description
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Time Frame
24 weeks
Title
Change of Systolic Blood Pressure in 48 Weeks
Description
The decrease of systolic blood pressure compared with baseline. Baseline is blood pressure in 0 week
Time Frame
48 weeks
Title
Change of Diastolic Blood Pressure in 2 Weeks
Description
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week
Time Frame
2 weeks
Title
Change of Diastolic Blood Pressure in 4 Weeks
Description
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week
Time Frame
4 weeks
Title
Change of Diastolic Blood Pressure in 8 Weeks
Description
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week
Time Frame
8 weeks
Title
Change of Diastolic Blood Pressure in 12 Weeks
Description
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Time Frame
12 weeks
Title
Change of Diastolic Blood Pressure in 24 Weeks
Description
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Time Frame
24 weeks
Title
Change of Diastolic Blood Pressure in 48 Weeks
Description
The decrease of diastolic blood pressure compared with baseline. Baseline is blood pressure in 0 week.
Time Frame
48 weeks
Title
Serum Estradiol in 24 Weeks
Description
Fasting blood samples are taken at 8:00-10:00.After quiescence for 1h and centrifuged (3500rpm/min * 15min), serum samples are extracted and preserved in -80 ℃. Use hemiluminescent radioimmunoassay to detect the level of estradiol in serum sample.
Time Frame
24 weeks
Title
Serum Estradiol in 48 Weeks
Time Frame
48 weeks
Title
Serum Testosterone in 24 Weeks
Description
Fasting blood samples are taken at 8:00-10:00.After quiescence for 1h and centrifuged (3500rpm/min * 15min), serum samples are extracted and preserved in -80 ℃. Use hemiluminescent radioimmunoassay to detect the level of testosterone in serum sample.
Time Frame
24 weeks
Title
Serum Testosterone in 48 Weeks
Time Frame
48 weeks
Title
Serum MDA in 24 Weeks
Description
Among many oxidative stress biological indicators,malondialdehyde (MDA),the secondary products of lipid peroxidation,is the most representative and most studied polyunsaturated fatty acid peroxidation. Fasting blood samples are taken at 8:00-10:00.After quiescence for 1h and centrifuged (3500rpm/min * 15min), serum samples are extracted and preserved in -80 ℃. Use ELISA to detect the level of MDA in serum samples.
Time Frame
24 weeks
Title
Serum MDA in 48 Weeks
Time Frame
48 weeks
Title
Serum 8-OHdG in 24 Weeks
Description
Reactive oxygen species (ROS) produced either endogenously or exogenously can attack lipid, protein and nucleic acid simultaneously in the living cells. In nuclear and mitochondrial DNA, 8-hydroxydeoxyguanosine (8-OHdG) is produced during DNA repair and its measurement be useful as a marker of DNA lesion. Fasting blood samples are taken at 8:00-10:00.After quiescence for 1h and centrifuged (3500rpm/min * 15min), serum samples are extracted and preserved in -80 ℃. Use ELISA to detect the level of 8-OHdG in serum samples.
Time Frame
24 weeks
Title
Serum 8-OHdG in 48 Weeks
Time Frame
48 weeks
Title
Serum HNE in 24 Weeks
Description
4 - hydroxy-nonyl acid (HNE) is a strong toxicity end product of lipid peroxidation. Fasting blood samples are taken at 8:00-10:00.After quiescence for 1h and centrifuged (3500rpm/min * 15min), serum samples are extracted and preserved in -80 ℃. Use ELISA to detect the level of HNE in serum samples.
Time Frame
24 weeks
Title
Serum HNE in 48 Weeks
Time Frame
48 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with essential hypertension. Initial hypertension, or without taking any antihypertensive for at least one month. Sexual active. Exclusion Criteria: Patients with secondary hypertension. Patients with malignant hypertension, coronary heart disease, diabetes, a history of syncope, bradycardia (heart rate <45 beats / min), atrioventricular block(Ⅱ or Ⅲ degree), sick sinus syndrome, congestive heart failure, a history of cerebral vascular accidents, serious hepatic and kidney dysfunction, a history of serious mental illness, pregnant, taking oral exogenous estrogens (including contraceptives), hysterectomy, breastfeeding, a history of alcohol or drug abuse, having serious conflict with sexual partner, severity sexual dysfunction. Patients refuse to answer questions, refuse to fill in the questionaires,or do not willing to take blood examination.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jing Yu, Professor
Phone
+86 0931 8942076
Email
yujing2304@126.com
First Name & Middle Initial & Last Name or Official Title & Degree
Ruixin Ma, Doctor
Phone
+86 13893102690
Email
mrxdr@sina.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jing Yu, Professor
Organizational Affiliation
Second Hospital of Lanzhou University
Official's Role
Study Chair
Facility Information:
Facility Name
The Second Hospital of Lanzhou University
City
Lanzhou
State/Province
Gansu
ZIP/Postal Code
730000
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ruixin Ma, Doctor
Phone
+86 13893102690
Email
mrxdr@sina.com
First Name & Middle Initial & Last Name & Degree
Jing Yu, Professor
Phone
+86 13893607559
Email
yujing2304@126.com
First Name & Middle Initial & Last Name & Degree
Jing Yu, Professor
First Name & Middle Initial & Last Name & Degree
Ruixin Ma, Doctor

12. IPD Sharing Statement

Citations:
PubMed Identifier
20019324
Citation
WRITING GROUP MEMBERS; Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wasserthiel-Smoller S, Wong ND, Wylie-Rosett J; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation. 2010 Feb 23;121(7):e46-e215. doi: 10.1161/CIRCULATIONAHA.109.192667. Epub 2009 Dec 17. No abstract available. Erratum In: Circulation. 2010 Mar 30;121(12):e260. Stafford, Randall [corrected to Roger, Veronique L]. Circulation. 2011 Oct 18;124(16):e425.
Results Reference
background
PubMed Identifier
12493255
Citation
Lewington S, Clarke R, Qizilbash N, Peto R, Collins R; Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet. 2002 Dec 14;360(9349):1903-13. doi: 10.1016/s0140-6736(02)11911-8. Erratum In: Lancet. 2003 Mar 22;361(9362):1060.
Results Reference
background
PubMed Identifier
17101936
Citation
Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J; ALLHAT Collaborative Research Group. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med. 2006 Nov 13;166(20):2191-201. doi: 10.1001/archinte.166.20.2191.
Results Reference
background
PubMed Identifier
12748199
Citation
Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003 May 21;289(19):2560-72. doi: 10.1001/jama.289.19.2560. Epub 2003 May 14. Erratum In: JAMA. 2003 Jul 9;290(2):197.
Results Reference
background
PubMed Identifier
19052124
Citation
Jamerson K, Weber MA, Bakris GL, Dahlof B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008 Dec 4;359(23):2417-28. doi: 10.1056/NEJMoa0806182.
Results Reference
background
PubMed Identifier
14761074
Citation
Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl. 2003 Dec;2:29-34. doi: 10.1080/08038020310021967.
Results Reference
background
PubMed Identifier
6115999
Citation
Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Report of Medical Research Council Working Party on Mild to Moderate Hypertension. Lancet. 1981 Sep 12;2(8246):539-43.
Results Reference
background
PubMed Identifier
9039073
Citation
Grimm RH Jr, Grandits GA, Prineas RJ, McDonald RH, Lewis CE, Flack JM, Yunis C, Svendsen K, Liebson PR, Elmer PJ. Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension. 1997 Jan;29(1 Pt 1):8-14. doi: 10.1161/01.hyp.29.1.8.
Results Reference
background
PubMed Identifier
12107602
Citation
Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A, Mugellini A. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol. 2002 Jun;58(3):177-80. doi: 10.1007/s00228-002-0456-3. Epub 2002 May 1.
Results Reference
background
PubMed Identifier
9799042
Citation
Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens. 1998 Oct;11(10):1244-7. doi: 10.1016/s0895-7061(98)00139-3.
Results Reference
background
PubMed Identifier
15819590
Citation
Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs. 2005;65(6):773-86. doi: 10.2165/00003495-200565060-00005.
Results Reference
background
PubMed Identifier
2003706
Citation
Wassertheil-Smoller S, Blaufox MD, Oberman A, Davis BR, Swencionis C, Knerr MO, Hawkins CM, Langford HG. Effect of antihypertensives on sexual function and quality of life: the TAIM Study. Ann Intern Med. 1991 Apr 15;114(8):613-20. doi: 10.7326/0003-4819-114-8-613.
Results Reference
background
PubMed Identifier
14700518
Citation
Fogari R, Preti P, Zoppi A, Corradi L, Pasotti C, Rinaldi A, Mugellini A. Effect of valsartan and atenolol on sexual behavior in hypertensive postmenopausal women. Am J Hypertens. 2004 Jan;17(1):77-81. doi: 10.1016/j.amjhyper.2003.08.016.
Results Reference
background
PubMed Identifier
12519665
Citation
Meston CM. Validation of the Female Sexual Function Index (FSFI) in women with female orgasmic disorder and in women with hypoactive sexual desire disorder. J Sex Marital Ther. 2003 Jan-Feb;29(1):39-46. doi: 10.1080/713847100.
Results Reference
background
PubMed Identifier
15841702
Citation
Wiegel M, Meston C, Rosen R. The female sexual function index (FSFI): cross-validation and development of clinical cutoff scores. J Sex Marital Ther. 2005 Jan-Feb;31(1):1-20. doi: 10.1080/00926230590475206.
Results Reference
background
PubMed Identifier
19487090
Citation
Krapf JM, Simon JA. The role of testosterone in the management of hypoactive sexual desire disorder in postmenopausal women. Maturitas. 2009 Jul 20;63(3):213-9. doi: 10.1016/j.maturitas.2009.04.008. Epub 2009 May 31.
Results Reference
background
PubMed Identifier
20092441
Citation
Basson R, Wierman ME, van Lankveld J, Brotto L. Summary of the recommendations on sexual dysfunctions in women. J Sex Med. 2010 Jan;7(1 Pt 2):314-26. doi: 10.1111/j.1743-6109.2009.01617.x.
Results Reference
background
PubMed Identifier
19527189
Citation
Basson R. Pharmacotherapy for women's sexual dysfunction. Expert Opin Pharmacother. 2009 Jul;10(10):1631-48. doi: 10.1517/14656560903004184.
Results Reference
background
PubMed Identifier
11224701
Citation
Berry C, Brosnan MJ, Fennell J, Hamilton CA, Dominiczak AF. Oxidative stress and vascular damage in hypertension. Curr Opin Nephrol Hypertens. 2001 Mar;10(2):247-55. doi: 10.1097/00041552-200103000-00014.
Results Reference
background
PubMed Identifier
11082160
Citation
Lacy F, Kailasam MT, O'Connor DT, Schmid-Schonbein GW, Parmer RJ. Plasma hydrogen peroxide production in human essential hypertension: role of heredity, gender, and ethnicity. Hypertension. 2000 Nov;36(5):878-84. doi: 10.1161/01.hyp.36.5.878.
Results Reference
background
PubMed Identifier
16409717
Citation
Agarwal A, Gupta S, Sharma R. Oxidative stress and its implications in female infertility - a clinician's perspective. Reprod Biomed Online. 2005 Nov;11(5):641-50. doi: 10.1016/s1472-6483(10)61174-1.
Results Reference
background
PubMed Identifier
18698219
Citation
Vlachopoulos C, Aznaouridis K, Ioakeimidis N, Rokkas K, Tsekoura D, Vasiliadou C, Stefanadi E, Askitis A, Stefanadis C. Arterial function and intima-media thickness in hypertensive patients with erectile dysfunction. J Hypertens. 2008 Sep;26(9):1829-36. doi: 10.1097/HJH.0b013e3283050886.
Results Reference
background
PubMed Identifier
19016153
Citation
Dincer Y, Sekercioglu N, Pekpak M, Gunes KN, Akcay T. Assessment of DNA oxidation and antioxidant activity in hypertensive patients with chronic kidney disease. Ren Fail. 2008;30(10):1006-11. doi: 10.1080/08860220802422044.
Results Reference
background
PubMed Identifier
16735834
Citation
Agarwal A, Gupta S, Sikka S. The role of free radicals and antioxidants in reproduction. Curr Opin Obstet Gynecol. 2006 Jun;18(3):325-32. doi: 10.1097/01.gco.0000193003.58158.4e.
Results Reference
background
PubMed Identifier
18360047
Citation
Ono H, Minatoguchi S, Watanabe K, Yamada Y, Mizukusa T, Kawasaki H, Takahashi H, Uno T, Tsukamoto T, Hiei K, Fujiwara H. Candesartan decreases carotid intima-media thickness by enhancing nitric oxide and decreasing oxidative stress in patients with hypertension. Hypertens Res. 2008 Feb;31(2):271-9. doi: 10.1291/hypres.31.271.
Results Reference
background
PubMed Identifier
19960026
Citation
de la Sierra A, Larrousse M. Endothelial dysfunction is associated with increased levels of biomarkers in essential hypertension. J Hum Hypertens. 2010 Jun;24(6):373-9. doi: 10.1038/jhh.2009.91. Epub 2009 Nov 26.
Results Reference
background
PubMed Identifier
20227347
Citation
Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlof B, Poulter NR, Sever PS; ASCOT-BPLA and MRC Trial Investigators. Effects of beta blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol. 2010 May;9(5):469-80. doi: 10.1016/S1474-4422(10)70066-1. Epub 2010 Mar 11.
Results Reference
background
PubMed Identifier
22134388
Citation
Ma R, Yu J, Xu D, Yang L, Lin X, Zhao F, Bai F. Effect of felodipine with irbesartan or metoprolol on sexual function and oxidative stress in women with essential hypertension. J Hypertens. 2012 Jan;30(1):210-6. doi: 10.1097/HJH.0b013e32834e1e2e.
Results Reference
derived

Learn more about this trial

Combined Antihypertensive Therapy and Sexual Dysfunction

We'll reach out to this number within 24 hrs